Form D · Biotechnology
Arch Therapeutics, Inc.
Natick, MA · CIK 0001502523
Offering snapshot reported Jun 20, 2013 · SEC filing
- Reported sold
- $370K Offering amount: $370K
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 19, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 20, 2013 | Initial | $370,397 | No comparison | 16 | SEC filing |
| Oct 5, 2010 | Initial | $75,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-198360
Source: Form D, filed Jun 20, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Bison | Executive |
| Avtar Dhillon | Director |
| Steven Kelly | Director, Executive |
| Terrence W. Norchi | Director, Executive |
| Arthur Rosenthal | Director |
| James Shannon | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Chieftain Lane
Natick, MA, 01760
Natick, MA, 01760